Texas § 549.0352 DRUG USE REVIEWS.

Texas Statutes

§ 549.0352 — DRUG USE REVIEWS.

Texas § 549.0352

Code GVGovernment Code

This text of Texas § 549.0352 (DRUG USE REVIEWS.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Government Code Code Ann. § 549.0352 (2026).

Text

Sec. 549.0352. DRUG USE REVIEWS.

(a)The commission shall provide for an increase in the number and types of retrospective drug use reviews performed each year under the Medicaid Drug Utilization Review Program in comparison to the number and types of reviews performed in the state fiscal year ending August 31, 2009.

(b)In determining the number and types of drug use reviews to be performed, the commission shall:

(1)allow for the repeat of retrospective drug use reviews that address ongoing drug therapy problems and that, in previous years, improved client outcomes and reduced Medicaid spending;

(2)consider implementing disease-specific retrospective drug use reviews that:

(A)address ongoing drug therapy problems in this state; and

(B)reduced Medicaid prescription drug use expenditure

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 549.0352. DRUG USE REVIEWS. (a) The commission shall provide for an increase in the number and types of retrospective drug use reviews performed each year under the Medicaid Drug Utilization Review Program in comparison to the number and types of reviews performed in the state fiscal year ending August 31, 2009.
(b) In determining the number and types of drug use reviews to be performed, the commission shall:
(1) allow for the repeat of retrospective drug use reviews that address ongoing drug therapy problems and that, in previous years, improved client outcomes and reduced Medicaid spending;
(2) consider implementing disease-specific retrospective drug use reviews that:
(A) address ongoing drug therapy problems in this state; and
(B) reduced Medicaid prescription drug use expenditures in another state; and
(3) regularly examine Medicaid prescription drug claims data to identify occurrences of potential drug therapy problems that may be addressed by repeating successful retrospective drug use reviews performed in this state or another state.